Research and Markets: SWOT Analysis of Chugai Pharmaceutical Co., Ltd. - Examine their Strengths, Weaknesses, Opportunities and Threats
|
| Posted
:
Mon, 06 Jul 2009 08:03:34 GMT |
| Author
:
Research and Markets
|
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
DUBLIN - (Business Wire) Research and Markets (http://www.researchandmarkets.com/research/5019b5/chugai_pharmaceuti) has announced the addition of the "Chugai Pharmaceutical Co., Ltd. - SWOT Analysis" company profile to their offering. The Chugai Pharmaceutical Co., Ltd. - SWOT Analysis company profile is the essential source for top-level company data and information. Chugai Pharmaceutical Co., Ltd. - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Chugai Pharmaceutical (Chugai), a subsidiary of the Roche Group, is engaged in biopharmaceutical research and development. It produces antibody drugs, focused in the three areas, oncology, renal diseases and bone and joint diseases. The company primarily operates in Europe, Americas and Asia Pacific. It is headquartered in Tokyo, Japan and employed 6,383 people as of December 2008. The company recorded revenues of JPY326,938 million (approximately $3,171.3 million-) during the financial year (FY) ended December 2008, a decrease of 5.2% over FY2007. The decrease was mainly due to the significant drop in Epogin sales when compared with that of previous year. The operating profit of the company was JPY51,563 million (approximately $500.2 million-) during FY2008, a decrease of 22.7% over FY2007. The net profit was JPY39,265 million (approximately $380.9 million-) in FY2008, a decrease of 2% over FY2007. -Calculated using the constant conversion rate of JPY1 = $0.0097 for the year ended December 2008. Scope of the Report - Provides all the crucial information on Chugai Pharmaceutical Co., Ltd. required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting Chugai Pharmaceutical Co., Ltd. in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Chugai Pharmaceutical Co., Ltd.
- Data is supplemented with details on Chugai Pharmaceutical Co., Ltd. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Chugai Pharmaceutical Co., Ltd.
Reasons to Purchase - Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available
For more information visit http://www.researchandmarkets.com/research/5019b5/chugai_pharmaceuti Source: Datamonitor Research and Markets Laura Wood Senior Manager press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716
|

Copyright © 2008
Business Wire. All rights reserved.
|
|
|
|
|
Related
News
TomTec Imaging Systems Strengthens Its Application Portfolio and Expertise in the Field of Radiologic Ultrasound MUNICH -
TomTec
Imaging Systems, the leading innovator for cardiac image analysis
a
BrightMove Releases BrightMove Quantify for Recruitment Outsourcing and HR Outsourcing
Jacksonville, FL based BrightMove Releases BrightMove Quantify(tm) -
For Recruiting Process Outsourcing (RPO) and Human Resource Process Outsourcing (HRO) providers/I/P
P(PRWEB) September 4, 2009 -- a href= http://www.brightmove.com/ onclick= linkClick( this.href ); target= _blank ...
WWF Reacts to Announcement that President Obama Will Attend UNFCCC Talks in Copenhagen
The following statement was issued today by World Wildlife Fund’s Climate Program Director Keya Chatterjee in response to the announcement that President Obama will attend the United Nations Framework Convention on Climate Change, which takes place in Copenhagen, Denmark from December 7...
Blue Square - Israel Ltd. Announces Financial Results for the Third Quarter and First Nine Months of 2009
ROSH HA'AYIN, Israel, November 25 --
- Expansion of the Private Brand "Mega ", Reaching 6% of the Sales,
Starting to Yield Fruits
Blue Square Reports stability in the Operating Profit Despite the
Increased Competition and One-Tim...
Fitch Rates J.P. Morgan Securities Inc. PUTTERs & DRIVERs, Series 3614 NEW YORK -
Fitch Ratings has assigned a rating of 'AA/F1+' to the puttable
tax-exempt receipts, series 3614 (PUTTERs) and a rating of 'AA' to the
derivative inverse tax-exempt receipts, series 3614 (DRIVERs). The
long-term rating assigned to the PUTTERs and DRIVERs is based on the
lon
Deerfield Capital Corp. Announces Transfer to the NASDAQ Stock Market
CHICAGO, Nov. 25 -- Deerfield Capital Corp. (NYSE AMEX: DFR) ("DFR" or the "Company") today announced that it expects to voluntarily transfer the listing of its common stock from the NYSE Amex LLC to the NASDAQ Stock Market LLC (the &quo...
American Water to Host Investor Conference on December 7 VOORHEES, N.J. -
American Water Works Company, Inc. (NYSE:AWK), the largest
investor-owned U.S. water and wastewater utility company, today
announced that it will host an Investor Conference on Monday, December 7
at the New York Stock Exchange. The event will take place from 12:30
p.m
|
|
|
|
|
|
|
|
|